Premium
Treatment of Helicobacter pylori infection 2017
Author(s) -
O'Connor Anthony,
Lamarque Dominique,
Gisbert Javier P.,
O'Morain Colm
Publication year - 2017
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12410
Subject(s) - clarithromycin , helicobacter pylori , medicine , helicobacter pylori infection , bismuth , mainstream , intensive care medicine , drug resistance , pharmacotherapy , antibiotic resistance , helicobacter infections , antibiotics , microbiology and biotechnology , political science , biology , materials science , law , metallurgy
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2016 to April 2017. The main themes that emerge involve studies assessing the efficacy of bismuth and nonbismuth quadruple regimens. While in recent years, much of the emphasis on the use of bismuth has focussed on its utility in a second‐line setting, an increasing number of studies this year have shown excellent efficacy in first‐line therapy. The efficacy of bismuth as a second‐line after sequential and concomitant therapy was particularly noteworthy. Antibiotic resistance was more intensely studied this year than for a long time, and definite trends are presented regarding an increase in resistance, including the fact that clarithromycin resistance in particular is now at a level where the continued use of clarithromycin triple therapy first‐line as a mainstream treatment is not recommended. Another exciting trend to emerge this year is the utility of vonoprazan as an alternative to PPI therapy, especially in resistant and difficult‐to‐treat groups.